Stanca Carmen M, Montazem Andre H, Lawal Adeyemi, Zhang Jin X, Schiano Thomas D
Mount Sinai Medical Center, Department of Medicine, New York, NY 10029, USA.
J Oral Maxillofac Surg. 2010 Jan;68(1):138-43. doi: 10.1016/j.joms.2009.07.081.
Cirrhotic patients waiting for liver transplantation who need dental extractions are given fresh frozen plasma and/or platelets to correct coagulopathy. This is costly and may be associated with transfusion reactions and fluid overload. We evaluated the efficacy of intranasal desmopressin as an alternative to transfusion to correct the coagulopathy of cirrhotic patients undergoing dental extraction.
Cirrhotic patients with platelet counts of 30,000 to 50,000/microL and/or international normalized ratio (INR) 2.0 to 3.0 were enrolled in a prospective, controlled, randomized clinical trial. Blood transfusion (fresh frozen plasma 10 mL/kg and/or 1 unit of single donor platelets, respectively) or intranasal desmopressin (300 microg) were given before dental extraction. A standard oral and maxillofacial surgical treatment protocol was performed by the same surgeon. Patients were followed for postextraction bleeding and side-effects over the next 24 to 48 hours.
No significant differences were noted between the 2 groups in gender, age, INR, platelet count, creatinine, total bilirubin, ALT, albumin, MELD score, or number of teeth removed (median 3 vs 4). The number of teeth removed ranged between 1 and 31 in the desmopressin group and 1 and 22 in the transfusion group. No patients in desmopressin group required rescue blood transfusion after extraction. One patient in the transfusion group had bleeding after the procedure and required an additional transfusion. Another patient experienced an allergic reaction at the end of transfusion, which was effectively treated with diphenhydramine. Treatment associated average costs were lower for desmopressin ($700/patient) compared with transfusion ($1,173/patient).
Intranasal desmopressin was as effective as blood transfusion in achieving hemostasis in cirrhotic patients with moderate coagulopathy undergoing dental extraction. Intranasal desmopressin was much more convenient, less expensive, and well tolerated.
等待肝移植的肝硬化患者若需要拔牙,会给予新鲜冰冻血浆和/或血小板以纠正凝血功能障碍。这成本高昂,且可能伴有输血反应和液体过载。我们评估了鼻内去氨加压素作为输血替代方法纠正接受拔牙的肝硬化患者凝血功能障碍的疗效。
血小板计数为30,000至50,000/微升和/或国际标准化比值(INR)为2.0至3.0的肝硬化患者被纳入一项前瞻性、对照、随机临床试验。在拔牙前给予输血(分别为10毫升/千克新鲜冰冻血浆和/或1单位单采血小板)或鼻内去氨加压素(300微克)。由同一位外科医生执行标准的口腔颌面外科治疗方案。在接下来的24至48小时内对患者进行拔牙后出血情况及副作用的随访。
两组在性别、年龄、INR、血小板计数、肌酐、总胆红素、谷丙转氨酶、白蛋白、终末期肝病模型(MELD)评分或拔牙数量(中位数分别为3颗和4颗)方面无显著差异。去氨加压素组拔牙数量在1至31颗之间,输血组在1至22颗之间。去氨加压素组无患者拔牙后需要挽救性输血。输血组有1例患者术后出血,需要额外输血。另1例患者在输血结束时出现过敏反应,用苯海拉明有效治疗。与输血(每位患者1173美元)相比,去氨加压素治疗相关的平均成本较低(每位患者700美元)。
鼻内去氨加压素在为中度凝血功能障碍的肝硬化拔牙患者实现止血方面与输血效果相同。鼻内去氨加压素更方便、成本更低且耐受性良好。